Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7752W HIGH $14.91
Volume
1.14 M
Value Traded
19.32 M
Short % Float
10.67%
+1.77%Week
+12.3%1 Month
+77.47%3 Month
-35.03%6 Month
-93.08%5 Year
-93.08%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
325.79 M
EPS (TTM)
1.54
P/E Ratio
3.72
Ent. Value
1.57 B
Total Shares
56.66 M
Float Shares
51.99 M
Insiders
8.24%
Institutions
85.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
EMBC Catalyst Timeline
Dated clinical, regulatory and corporate events for Embecta Corp.
Past FDA Catalysts and PDUFA Decisions
How EMBC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Embecta Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every EMBC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Morris Milton MayoDirector | Sell | -6,293 53,828.34 held | $5.88 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EMBC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| KRENSAVAGE ASSET MANAGEMENT, LLC | 1.4 % (-44 %) | 3.70 M | 1.14 M | 54.4% ( 400.00 K) |
EMBC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EMBC ranks across every disease it competes in
Competitive Position is a premium feature
See how EMBC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEMBC News
EMBCembecta Completes Acquisition of Owen Mumford Holdings Limited
Embecta Corp. has successfully completed its acquisition of Owen Mumford Holdings Limited, a UK-based medical device innovator, for an upfront payment of $100 million and additional performance-based payments. This transaction aims to bolster embecta's transformation into a comprehensive medical supplies company, enhancing its capabilities in drug delivery systems, particularly for chronic care patients. The acquisition includes the next-generation Aidaptus auto-injector platform, which offers potential for future pharmaceutical partnerships. By merging their strengths, both companies expect to achieve greater operational efficiencies and expand their market reach.
Read more →EMBC▼ -57.8%on this news
Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results Lowers fiscal year 2026 financial guidance due to dynamics impacting U.S. business updated guidance also includes impact of the impending Owen Mumford acquisition
Embecta Corp. reported disappointing financial results for Q2 FY 2026, with a significant decline in revenues, particularly in the U.S. market. The company has lowered its fiscal year guidance due to these challenges, along with initiating a review of its cost structure. Despite these setbacks, Embecta remains optimistic about its strategic direction, particularly with the pending acquisition of Owen Mumford expected to close in May 2026. The company also authorized a $100 million share repurchase program while reducing its dividend to maintain financial flexibility.
Read more →EMBCembecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited
Embecta Corp. has announced a definitive agreement to acquire Owen Mumford Holdings Limited for up to $150 million, aimed at enhancing its capabilities in the drug-delivery devices sector. The acquisition includes an upfront payment of $100 million and potential performance-based payments of up to $50 million. The deal is anticipated to close in the fiscal third quarter of 2026, subject to regulatory approvals. This strategic move is set to bolster embecta's revenue growth and facilitate its transition into a broader medical supplies company, leveraging Owen Mumford's innovations and existing commercial infrastructure.
Read more →EMBC▼ -7.8%on this news
Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results
Embecta Corp. reported its financial results for the first quarter of fiscal 2026, with total revenues of $261.2 million, a slight decrease compared to the previous year. U.S. revenues declined by 7.6%, although international revenues showed an 8.4% increase. The company is focusing on transforming into a broader medical supplies entity, while making strides in reducing debt and maintaining dividends. Despite the challenges in the U.S. market, overall financial guidance remains unchanged.
Read more →EMBC▼ -7.2%on this news
Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results Provides Initial Fiscal Year 2026 Financial Guidance
Embecta Corp. reported its financial results for the fourth quarter and full year of fiscal 2025, noting a decline in revenue. While the company showed improvements in profitability metrics, such as operating margin and net income, overall revenues fell due to challenges in the domestic and international markets. Management remains optimistic about future growth, emphasizing debt reduction and strategic initiatives aimed at increasing operational efficiency and product offerings in fiscal year 2026.
Read more →EMBCembecta announces changes to Board of PARSIPPANY, N.J., Nov. 17, 2025 -- Embecta Corp. ("embecta")
Embecta Corp. has announced significant changes to its Board of Directors, as David J. Albritton has resigned for personal reasons and LTG (Ret.) David F. Melcher will not seek re-election in 2026. The current leadership has expressed gratitude for the departing members' contributions during the company's establishment phase. Future appointments to the board are expected, ensuring continuity in strategic direction as embecta shifts focus towards growth in the medical supplies sector. The company aims to enhance its corporate governance amidst these transitions.
Read more →EMBC▲ +18.5%on this news· ran to +35% by day 3
Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results
Embecta Corp. reported strong financial results for Q3 FY2025, with revenues increasing 8.4% year-over-year to $295.5 million. The quarter's success was attributed to effective commercial execution and the implementation of a new ERP system and distribution centers in India. While U.S. revenues increased by 11.6%, total revenues for the nine-month period ended June 30, 2025, declined by 2.5%. The company remains focused on diversifying its medical supplies offerings and enhancing operational capabilities despite a complex geopolitical landscape.
Read more →EMBC▼ -10%on this news
Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results
Embecta Corp. reported its financial results for the second quarter of fiscal year 2025, showing a decrease in revenues of 9.8% year-over-year. Despite this decline, the company's financial performance was slightly better than expected, with adjusted earnings per share guidance unchanged. The report highlighted ongoing challenges, including decreased U.S. and international revenues. Embecta's strategic initiatives include a successful restructuring program and advancements in product offerings.
Read more →EMBCEmbecta Corp. Reports First Quarter Fiscal 2025 Financial Results
Embecta Corp. reported financial results for the first quarter of fiscal year 2025, revealing a decline in revenues to $261.9 million, down 5.6% year-over-year. Despite the downturn, the company expects to enhance its financial outlook and continue its strategic restructuring. Notably, Embecta's adjusted earnings per diluted share improved slightly, indicating some resilience in its core business amid ongoing market challenges. The company is set to launch its brand transition plan later in the year and remains optimistic about its long-term strategy.
Read more →EMBC▲ +29.8%on this news· ran to +43% by day 3
Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results Provides Initial Fiscal Year 2025 Financial Guidance Discontinues Insulin Patch Pump Program and Announces Restructuring to Streamline Oper
Embecta Corp. announced its financial results for the fourth quarter and full year of fiscal 2024, reporting $286.1 million in revenues, a 1.5% increase from the previous period. The company also disclosed a restructuring plan that will discontinue its insulin patch pump program, aiming to streamline operations and reduce costs. Total pre-tax charges related to the restructuring are expected to be between $35 million and $45 million for fiscal year 2025. Despite these challenges, Embecta reported strong performance in its core business and successful product launches.
Read more →EMBC▲ +7.3%on this news
Document FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2024 Financial Results PARSIPPANY, N.J.
Embecta Corp. reported its third quarter fiscal 2024 financial results, showing a revenue decline of 4.8% year-over-year to $272.5 million. Despite this drop, the company maintained strong gross and operating margins, with significant advancements in strategic goals and an increased fiscal outlook. The implementation of a new ERP system and progress on key product developments, such as their open-loop patch pump program, were highlighted. The company declared a quarterly cash dividend, reaffirming its financial stability.
Read more →EMBC▲ +37.9%on this news
Document FOR IMMEDIATE RELEASE Embecta Corp. Reports Second Quarter Fiscal 2024 Financial Results PARSIPPANY, N.J.
Embecta Corp. reported its financial results for the second quarter of fiscal 2024, revealing a revenue increase of 3.6% compared to the same period last year. Despite the increase, the company noted a decline in both gross profit margin and operating income. The CEO highlighted operational successes and improvements in ERP systems, while the firm raised its financial outlook for the year due to strong performance. Additionally, the company declared a quarterly cash dividend of $0.15 per share.
Read more →EMBC▼ -8.5%on this news
Document FOR IMMEDIATE RELEASE Embecta Corp. Reports First Quarter Fiscal 2024 Financial Results PARSIPPANY, N.J.
Embecta Corp. has reported its financial results for the first quarter of fiscal 2024, showing a revenue increase of 0.6% to $277.3 million, despite a slight decrease in U.S. revenues. The company is successfully integrating approximately 60% of its revenue into a new ERP system and is raising its financial guidance for the year. Nevertheless, key metrics like operating income and net income saw significant declines from the prior year, highlighting ongoing challenges despite some strategic advancements.
Read more →EMBCEmbecta Corp. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Provides Initial Fiscal 2024 Financial Guidance PARSIPPANY, N.J.
Embecta Corp. announced its financial results for the fourth quarter and full fiscal year 2023, marking its first complete year as an independent entity. The company experienced a 2.7% increase in fourth-quarter revenues, with a reported net income of $6.0 million. For fiscal year 2024, Embecta forecasts a decline in revenues of 1.0% to 3.0% on a reported basis but continues to focus on its strategic priorities, including the development of a closed loop insulin delivery system. The company also declared a quarterly dividend of $0.15 per share.
Read more →EMBCEmbecta Corp. Reports Third Quarter Fiscal 2023 Financial Results PARSIPPANY, N.J.
Embecta Corp. reported its third quarter fiscal 2023 results, reflecting a revenue decrease of 1.7% to $286.1 million. Despite this decline, the company increased its fiscal outlook for 2023, citing strong year-to-date performance. Embecta emphasized ongoing investments and strategic initiatives to strengthen its base business while separating from its former parent company, BD. The results included a decrease in gross profit margins and U.S. revenues, but the international segment showed some positive trends.
Read more →EMBC▲ +6.1%on this news
Embecta Corp. Reports Second Quarter Fiscal 2023 Financial Results PARSIPPANY, N.J.
Embecta Corp. reported its second quarter fiscal 2023 financial results, showing revenues of $277.1 million, a slight increase from the previous year. The company's CEO stated that results surpassed internal expectations, prompting an upward revision of revenue guidance for the fiscal year. However, while U.S. revenues grew, international revenues saw a decline. Additionally, net income and operating margins showed notable decreases from the same period last year.
Read more →EMBC▲ +12.6%on this news
Embecta Corp. Reports First Quarter Fiscal 2023 Financial Results PARSIPPANY, N.J.
Embecta Corp. reported its first-quarter fiscal 2023 financial results, achieving revenues of $275.7 million despite a 4.7% decline year-over-year. The company is optimistic about its performance, raising guidance for key financial metrics as it focuses on strategic priorities including business strengthening and growth investments. The results include a notable decrease in both U.S. and international revenues, although adjusted figures showed some positive trends amid challenging market conditions. The company continues to make strides in separation from Becton, Dickinson and Company and plans for future growth.
Read more →EMBC▼ -15.6%on this news
to our Current Report on Form 8-K and our most recent Annual Report on Form 10-K, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter. Except as required by law, we undertake no
Embecta Corp. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results PARSIPPANY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) - Embecta Corp. ("embecta") (Nasdaq EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for th
Read more →EMBC▲ +16.5%on this news
to our Current Report on Form 8-K. Except as required by law, we undertake no obligation to update any forward-looking statements appearing in this release. CONTACTS Investors Pravesh Khandelwal VP, Head of Investor Rela
Embecta Corp. Reports Third Quarter Fiscal 2022 Financial Results PARSIPPANY, N.J., Aug 15, 2022 (GLOBE NEWSWIRE) - Embecta Corp. ("embecta") (Nasdaq EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dicki
Read more →EMBC▼ -8.8%on this news
to our Current Report on Form 8-K. Except as required by law, we undertake no obligation to update any forward-looking statements appearing in this release. CONTACTS Investors https investors.embecta.com shareholder-serv
Embecta Corp. Reports Second Quarter and First Six Months of Fiscal Year 2022 Financial Results and Provides Financial Guidance for the Last Six Months of Fiscal Year 2022 Parsippany, N.J., May 13, 2022 (GLOBE NEWSWIRE) - Embecta Corp. ("embecta") (Nasdaq EMBC), one of the large
Read more →About Embecta Corp.
Headquarters300 KIMBALL DRIVE, PARSIPPANY, NJ, 07054
BIOPHARMAWATCH ELITE PLUS
Trade the next EMBC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime